Norwegen - Norwegisch - Statens legemiddelverk

orifarm as - pantoprazolnatriumsesquihydrat - enterotablett - 20 mg

Norwegen - Norwegisch - Statens legemiddelverk

orifarm as - pantoprazolnatriumsesquihydrat - enterotablett - 20 mg

Norwegen - Norwegisch - Statens legemiddelverk

orifarm as - pantoprazolnatriumsesquihydrat - enterotablett - 40 mg

Norwegen - Norwegisch - Statens legemiddelverk

orifarm as - okskarbazepin - tablett, filmdrasjert - 300 mg

Norwegen - Norwegisch - Statens legemiddelverk

orifarm as - okskarbazepin - tablett, filmdrasjert - 300 mg

Norwegen - Norwegisch - Statens legemiddelverk

orifarm as - okskarbazepin - tablett, filmdrasjert - 600 mg

Norwegen - Norwegisch - Statens legemiddelverk

orifarm as - okskarbazepin - tablett, filmdrasjert - 600 mg

Norwegen - Norwegisch - Statens legemiddelverk

orifarm as - okskarbazepin - tablett, filmdrasjert - 600 mg

Europäische Union - Norwegisch - EMA (European Medicines Agency)

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - dengue - vaksiner - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 og 4. bruk av dengvaxia skal være i samsvar med offisielle anbefalinger.

Europäische Union - Norwegisch - EMA (European Medicines Agency)

mylan ireland limited - sugammadex sodium - neuromuskulær blokkade - alle andre terapeutiske produkter - reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.